COPD

Nucala is for use with other asthma drugs for the maintenance of patients 12 years and older.

Health application allows patients to report respiratory symptoms and peak flow measurements from COPD.

Drop in physical activity level linked to increased airflow obstruction.

Drugs are delivered via the low-resistance Neohaler inhaler.

For patients with chronic obstructive pulmonary disease (COPD), fear during episodes of breathlessness, dyspnea during typical daily activities, and depressive symptoms may be good predictors of hospitalization.

The FDA has approved 2 Novartis inhalation powders for the treatment of COPD.

Caregivers are urged to utilize adequate mental health screening approaches.

Process can improve medical care with better results for patients.

Community level factors linked to COPD include rural residence, southern residence, and community poverty.

Grants expected to lead to development of wearable and non-wearable sensors to track environmental exposures and physiological signals in a natural environment.

Vitamin D deficiency may speed progression of the condition.

Roflumilast normally treats inflammatory lung diseases, but was found to dramatically inhibit tumor growth.

Inpatient hospitalization and emergency department visits are key cost drivers for patients.

Asthma and chronic obstructive pulmonary disease (COPD) occur together at an alarming rate.

Childhood pneumonia carries a higher risk of chronic bronchitis and other disease-related quality of life issues.

Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses how MinuteClinic enhances COPD management.

GOLD group classification system could not predict lung function decline.

Patients who received immediate treatment recommendations saw improved symptom control.

The FDA has added an asthma indication to Boehringer Ingelheim's tiotropium bromide inhalation spray (Spiriva Respimat).

Aclidinium bromide and formoterol provide an additional benefit over the traditional therapy regimen.

Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses the biggest roadblocks to managing COPD and how pharmacists can help overcome those challenges.

Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses some techniques pharmacists can demonstrate for inhaled medications like Dulera and Symbicort.

Pharmacist intervention can reduce 30- and 60-day readmissions with accompanying cost savings.

Both conditions are separate diseases with different causes, diagnostic procedures, and treatments.

Minor benefit found adult patients with grade II, or moderate, COPD when adding aclidinium bromide and formoterol.

Several advancements have been made in COPD medication classes.

Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses some counseling points pharmacists can provide to patients on COPD medications.

A list of the most debilitating diseases a patient may face over his or her lifetime was recently curated by Healthcare Business and Technology.

Multidose medication dispensing at discharge (MMDD) involves supplying products that have been partially used during hospitalization to ensure continuity of care.

Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses some strategies pharmacists can use to support COPD management.